Clinical Trial Update: Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial assessing paricalcitol for reducing proteinuria in kidney transplant recipients completed, examining efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Albuminuria
• Kidney Transplant Disorder
• Proteinuria

Drugs mentioned

• Paricalcitol (paricalcitol)

Snippet

Sponsor: University Medical Centre Ljubljana | Conditions: Disorder of Transplanted Kidney, Proteinuria | Phase 3 | Status: COMPLETED